Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
4
Expiration
Jan 19, 2029
DTE
822d
Moneyness
ITM
Intrinsic
$4.48
IBRX 4 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $6.06 | -3.35% | 1 | 53 |
| Oct 30, 2026 | 10d | $5.40 | +25.58% | 6 | 6 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $5.45 | -12.10% | 16 | 48 |
| Nov 27, 2026 | 38d | $5.40 | -11.48% | 2 | 1 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $5.70 | -6.10% | 1 | 5,546 |
| Mar 19, 2027 | 150d | $6.49 | -3.99% | 223 | 236 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | $4.24 | +0.00% | 1 | 1 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $6.75 | -1.75% | 15 | 2,170 |
| Mar 17, 2028 | 514d | $5.25 | -9.48% | 2 | 1 |
| Jan 19, 2029 | 822d | $7.20 | +1.55% | 3 | 22 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.